Dietary fatty acids and risk of Alzheimer’s disease and related dementias: Observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP)

Deborah R. Gustafson1,2 | K. Bäckman2 | N. Scarmeas3,4 | Y. Stern3 | J.J. Manly3 | R. Mayeux3,5 | Y. Gu3,5

1 Department of Neurology, State University of New York Downstate Health Sciences University, Brooklyn, New York, USA
2 Department of Neurochemistry and Psychiatry, Neuropsychiatric Epidemiology Unit, at the Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
3 Department of Neurology, The Gertrude H. Sergievsky Center, Taub Institute for Research in Alzheimer’s Disease and the Aging Brain, Columbia University and The New York Presbyterian Hospital, New York, New York, USA
4 1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece
5 The Department of Epidemiology, Joseph P. Mailman School of Public Health, Columbia University, New York, New York, USA

Abstract

Introduction: High dietary intake of long chain, polyunsaturated fatty acids is associated with lower Alzheimer’s disease (AD) risk.

Methods: Washington Heights-Hamilton Heights-Inwood Columbia Aging Project is a multiethnic, prospective observational study of aging and dementia among elderly (≥ 65 years). Dietary intake was measured using a food frequency questionnaire. Dietary short-, medium-, and long-chain fatty acid intakes were categorized by number of carbons and double bonds. Consensus AD diagnoses were made. Associations between AD risk and dietary fatty acid and cholesterol intakes were estimated using multivariable Cox proportional hazards regression models.

Results: Of 2612 multiethnic women (67%) and men (baseline age 76.3 [6.4] years), 380 developed AD over an average 4.5 years follow-up. Lower risk of AD was associated with increasing intakes of docosahexaenoic acid (DHA; hazard ratio [HR] = 0.73, 95% confidence interval [CI]: 0.57 to 0.95, \( P = 0.018 \)) and eicosapentaenoic acid (EPA; \( HR = 0.74, 95\% CI: 0.57 \) to 0.95, \( P = 0.021 \)), and longer AD-free survival (\( P < 0.05 \)).

Discussion: Higher intake of DHA and EPA are protective for AD.

Keywords: Alzheimer’s disease and related dementias (ADRD), cholesterol, DHA, diet, EPA, fatty acids, omega-3, risk factor
1 | INTRODUCTION

High dietary intake of long chain, polyunsaturated fatty acids (LC-PUFAs) is associated with lower risk for Alzheimer’s disease (AD) and related dementias (ADRD) in epidemiological and clinical research studies. High intake of fish1-3 and unsaturated fatty acids4-7 have been associated with reduced ADRD risk and/or cognitive decline. Data also suggest that intake of the Mediterranean diet or healthy dietary patterns that are high in LC-PUFAs are also protective for ADRD and ADRD mortality.2,5 In a clinical trial of omega-3 dietary supplements (1.7 g docosahexaenoic acid [DHA] + 0.6 g eicosapentaenoic acid [EPA]), there was a reduction in cognitive decline among those with a baseline Mini-Mental State Examination (MMSE) > 27 within the first 6 months.6 Despite the focus on and evidence for dietary LC-PUFAs in association with ADRD, the associations between dietary intake of other fatty acids that differ by chain length and/or degree of saturation and ADRD risk is underexplored.

Disentangling associations of multiple, heterogeneous dietary components, both traditional nutrients and non-nutrients, with human health, has sometimes been addressed using biochemical classifications. Dietary fat, one macronutrient of three in the human diet, is comprised of several very different molecules, primarily cholesterol and other sterols, fatty acids, and triglycerides (glycerol + fatty acids).10 Dietary fatty acids (carboxylic aliphatic acids with the general formula H(CH2)nCOOH), have been of utmost interest because of their chemical and functional diversity.11 Fatty acids differ in chain length (number of carbons) and degree of saturation or hydrogenation (number of double bonds). These characteristics contribute to distinct chemical properties, biological functionality, and physiological roles.12 As a result, dietary fatty acids have been chemically classified based on length (short, medium, and long carbon chains), and degree of hydrogen saturation, in addition to the presence of specific functional groups at the carboxylic end. Notably, there is not 100% agreement as to what carbon chain lengths constitute the definitions of short-, medium-, and long.10,12,14

LC-PUFAs have been of interest because they are concentrated in certain foods such as cold-water fish, vegetable oils, nuts, and seeds, and are highly bioactive molecules that are associated with human health and disease.15,16 Once incorporated into cell membranes, LC-PUFAs confer enhanced flexibility, in contrast to saturated fatty acids (FAs) and cholesterol, which contribute to a more rigid cell membrane. LC-PUFAs also function as cell signaling molecules, are involved in neurotransmitter biosynthesis, and regulate membrane-bound enzymes and eicosanoid production. Certain LC-PUFAs, such as DHA, are highly concentrated in the human retina and brain.16

Despite the distinct chemical properties and potential health benefits of distinct individual or classes of fatty acids, few concrete public health recommendations have been made. In the United States, as of the most recent update in 2005, dietary reference intakes (DRI) for adults age 18 years and older exist for total fat (20% to 35% of total energy intake), omega-6 PUFA (5% to 10% of total energy intake), and omega-3 PUFA (0.6% to 1.2% of total energy intake). Dietary intake of total cholesterol, trans-fatty acids, and saturated fatty acids are recommended to be “as low as possible while consuming a nutritionally adequate diet.”17 Adequate intake (AI) guidelines, defined when there is insufficient evidence to set a DRI, were set for adults age 51 years and older for the essential omega-6 fatty acid, alpha-linolenic acid (men: 14 g/d, women: 11 g/d) and the omega-3 fatty, alpha-linolenic acid (men: 1.6 g/d, women: 1.1 g/d).17 Given the low in vivo conversion efficiency of dietary alpha-linolenic and alpha-linolenic acid to DHA and EPA, some also deem DHA and EPA to be essential fatty acids.16

Due to the paucity of literature on more in-depth exploration of fatty acids, we explored the association between dietary fatty acid and cholesterol intake with AD and ADRD risk in a multiethnic, longitudinal, population study, the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP). Our hypothesis was that LC-PUFAs are more likely protective for AD and ADRD than short- or medium-chain fatty acids, and that saturated fatty acids and cholesterol increase risk for AD. To disentangle various classifications of dietary fatty acids that are often used, we considered three different fatty acid classifications based on published definitions of short-, medium-, and long-chain fatty acids, as well as degree of saturation. Intake of certain individual fatty acids was also considered.

RESEARCH IN CONTEXT

1. Systematic review: Dietary intake is a modifiable lifestyle factor for Alzheimer’s disease and related dementias (ADRD). Long chain fatty acids, such as those found in fish, nuts and seeds, and plant oils are associated with reduced ADRD risk. From a nutritional biochemistry perspective, little is known about possible differential associations of ADRD and fatty acids by carbon chain length or degree of saturation.

2. Interpretation: Population-based data from >2600 participants in the multiethnic Washington Heights-Hamilton Heights-Inwood Columbia Aging Project, suggest an exclusive association between ADRD-free survival and high intake of two omega-3 fatty acids, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), compared to intake of other saturated or unsaturated long chain-, medium-, or short-chain fatty acids, total fat, or cholesterol.

3. Future Directions: These data support the need for dietary intake recommendations for EPA and DHA because they are insufficiently produced by the human body and are modifiable risk factors that promote ADRD-free survival.
2 | METHODS

2.1 | Study population

The WHICAP study includes participants in two related cohorts who were recruited in 1992 and 1999. Participants were recruited from a probability sample of Medicare beneficiaries residing in northern Manhattan, New York. At study entry, a physician elicited each participant’s medical and neurological histories and conducted standardized physical and neurological examinations. Each participant also underwent a structured in-person interview including an assessment of health and function, and a neuropsychological battery. A global summary score based on the Clinical Dementia Rating was assigned. Participants were followed at intervals of ≈1.5 years, repeating the baseline examination and consensus diagnosis.

2.2 | ADRD diagnosis

A consensus diagnosis for the presence or absence of incident ADRD was made at a diagnostic conference attended by neurologists and neuropsychologists, using the neuropsychological battery of tests and evidence of cognitive deficit (based on the neuropsychological scores), evidence of impairment in social or occupational function (as assessed by the Blessed Dementia Rating Scale, the Schwab and England Activities of Daily Living Scale, and the physician’s assessment), and evidence of cognitive and social/occupational function decline compared to the past, as required by the Diagnostic and Statistical Manual of Mental Disorders (Third Edition Revised). The type of dementia was subsequently determined. For the diagnosis of probable or possible AD, the criteria of the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer Disease and Related Disorders Association were used. Because, according to the criteria, stroke does not preclude the diagnosis of AD (unless cerebrovascular disease is considered the primary cause of the dementia), the diagnosis of AD with concomitant stroke was also assigned. Therefore, dementia cases with cerebrovascular damage could be classified either in the non-AD dementia category or in the AD category. Diet data were not available to the diagnostic consensus panel and were not considered in the diagnostic process. The diagnostic consensus conferences took place on a continuous basis from the beginning of the study (i.e., every few months as completed participants’ evaluations were accumulated). Because WHICAP has been ongoing for more than 25 years, different neurologists and neuropsychologists have been participating at the consensus diagnoses over time, but always using the same diagnostic criteria.

2.3 | Dietary data

Average food consumption during the year before the baseline assessment was obtained in the majority of the cohort via one administration of a 61-item version of the semi-quantitative Harvard food frequency questionnaire (FFQ) (Channing Laboratory, Cambridge, Massachusetts). Trained interviewers administered the FFQ in English or Spanish. Validity and reliability of these FFQs to estimate nutrient intake among elderly participating in WHICAP has been evaluated. The daily intake of nutrients, with a focus on individual fatty acids and classes of fatty acids, was estimated by multiplying the intake frequency of each portion of every food listed on the FFQ by the nutrient content of the specified portion. Dietary intake was adjusted for total energy intake.

2.3.1 | Dietary fatty acid categories

Dietary fatty acids were classified in three ways—Classifications 1, 2, and 3—based on published definitions of short, medium, and long chains, as well as degree of saturation (see Table 1). In addition, given the higher prevalence of certain fatty acids and fatty acid groups in the human diet, desired comparisons of PUFAs with LC saturated FAs, and the goodness of the nutrient data base, we evaluated certain fatty acids or groups of fatty acids individually. These included: total saturated fats, total PUFAs, total monounsaturated fatty acids, total omega-3 and omega-6 fatty acids, two omega-3 fatty acids, EPA (20:5), and DHA (22:5); the monounsaturated fat, oleic acid (18:1); and two long-chain saturated fatty acids, palmitate (16:0) and stearate (18:0). Chain length only is considered in Classifications 1 and 2. Number of double bonds is considered in addition to chain length with evaluation of Classification 3, and the individual fatty acids or groups.

2.4 | Covariates

A variety of potential covariates were evaluated in relation to analyses of dietary fatty acid intake and AD. Information about recruitment cohort, age, sex, education, race/ethnicity, body mass index (calculated as weight in kilograms divided by height in meters squared), and smoking status were obtained from baseline interviews. Daily total energy intakes were calculated from the baseline FFQ administered at one time point. A modified version of the Charlson Comorbidity Index (hereafter referred to as the “comorbidity index”) included items for myocardial infarction, congestive heart failure, peripheral vascular disease, hypertension, chronic obstructive pulmonary disease, arthritis, gastrointestinal disease, mild liver disease, diabetes, chronic renal disease, and systemic malignancy from the initial visit. All items received weights of 1, with the exception of chronic renal disease and systemic malignancy, which were weighted 2. The comorbidity index was treated as a continuous variable. Possession of the apolipoprotein E (APOE)ε4 allele was also considered.

2.5 | Statistical analyses

Independent samples t tests were used to compare incident ADRD versus no ADRD on a variety of baseline continuous sociodemographic factors. Chi-square tests were used for categorical variables. Multivariate Cox proportional hazards models were used to evaluate
### TABLE 1 Dietary fatty acid classifications based on carbon chain length and number of double bonds, and individual fatty acids and fatty acid groups evaluated in association with Alzheimer’s disease and related dementia risk and survival in the Washington Heights-Inwood Columbia Aging Project

| Classification | Short chain (carbon number) | Medium chain (carbon number) | Long chain (carbon number) | Very long chain (carbon number) |
|----------------|-----------------------------|-------------------------------|---------------------------|---------------------------------|
| 1              | 2-6                         | 8-14                          | ≥16                       | NA                              |
| 2              | 2-4                         | 6-12                          | 14-22                     | 24-26                           |
| 3*             | NA                          | NA                            | Saturated: 12+, 14+, 16+   | Unsaturated: 16+                 |

**Individual fatty acids or groups**

- **Omega-3** fatty acids, total
  - Eicosapentaenoic acid (EPA, 20:5)
  - Docosahexaenoic acid (DHA, 22:5)

- **Omega-6 fatty acids, total**
  - Monounsaturated fatty acids, total
    - Oleic acid (18:1)
  - Long-chain saturated fatty acids, total
    - Palmitic acid (16:0)
    - Stearic acid (18:0)
  - Long-chain polyunsaturated fatty acids, total

*Chain length only is considered with Classifications 1 and 2. Number of double bonds is considered in addition to chain length with evaluation of Classification 3 and the Individual fatty acids or group.

**RESULTS**

At baseline, there were N = 2647 participants without dementia and with dietary intake information. Of these, N = 2612 participants (67.4% women) reported an average daily energy intake of 500 to 3500 kilocalories (a range deemed to be “healthy”). Participants were followed for an average of 4.5 years. Over this follow-up period, N = 406 developed ADRD (12 008 person-years at risk; incidence rate of 3.3%), and of these, N = 380 (93.6% of ADRD cases) developed AD (11 869 person-years at risk). Baseline characteristics of WHICAP participants with dietary intake information are presented in Table 2. Notably, at baseline, compared to those who remained free of ADRD, higher age and lower education were associated with incident ADRD. In addition, the representation of various racial groups was not uniform. Dietary intake of total fat and cholesterol in the sample were comparable to those typically reported in other aging cohort studies as evidenced by Table 3 median intakes by tertile.

Consideration of different fatty acid classifications based on chain length and degree of saturation did not shed additional light on AD risk associations. Of all fatty acid categories evaluated, intakes of DHA and EPA were related to the lowest AD risk and longest ADRD-free survival (P < 0.05, Table 3, Figures 1 and 2). A 27% lower risk of AD was observed for DHA and 26% lower AD risk for EPA, comparing intakes in the highest tertile compared to the lowest tertile. Intake of dietary cholesterol was associated with a 38% higher risk of AD (P < 0.05). Intake of very long chain fatty acids (24 to 26 carbons) was not represented in these data. Results associating fatty acids and cholesterol to ADRD (all dementias) were similar in all essential aspects to those for AD.
TABLE 2  Washington Heights–Inwood Columbia Aging Project sample baseline characteristics of those who developed Alzheimer’s disease and related dementia (ADRD) and those who remained ADRD-free over the course of longitudinal follow-up

| Variable                        | ADRD (406) | No ADRD (2206) | All (2612) | ADRD vs no ADRD P-value |
|---------------------------------|------------|----------------|------------|-------------------------|
| Women, n (%)                    | 278 (68.5) | 1483 (67.2)    | 1761 (67.4)| 0.622                   |
| Age (years), mean (SD)          | 78.8 (6.8 )| 75.9 (6.3)     | 76.3 (6.4 )| <0.0001                 |
| Ethnicity                       |            |                |            |                         |
| White, n (%)                    | 52 (12.8)  | 678 (30.7)     | 730 (27.9) | <0.0001                 |
| Black, n (%)                    | 124 (30.5 )| 715 (32.4)     | 839 (32.1 )|                         |
| Hispanic, n (%)                 | 226 (55.7 )| 782 (35.4)     | 1008 (38.6)|                         |
| Other, n (%)                    | 4 (1.0)    | 31 (1.4)       | 35 (1.3)   |                         |
| Any APOE ε4 allele, n (%)a      | 120 (31.7) | 514 (26.9)     | 634 (27.6) | 0.056a                  |
| Education (years), mean (SD)b   | 7.5 (4.7)  | 10.5 (4.7)     | 10.0 (4.8 )| <0.0001b                |
| Body mass index (kg/m²)         | 27.3 (5.8) | 27.8 (5.3)     | 27.7 (5.4 )| 0.168                   |
| Energy intake (kilocalories), mean (SD)c | 1488.4 (546.3) | 1433.8 (494.0) | 1442.25 (502.7) | 0.0439c           |
| Smoking, n (%)                  | 48 (11.8)  | 252 (11.4)     | 300 (11.5) | 0.8166                  |
| Number of comorbidities, mean (SD) | 2.3 (1.6) | 2.2 (1.5)     | 2.2 (1.5) | 0.3739d                |
| CDR > 0, n (%)                  | 173 (44.5) | 339 (15.6)     | 512 (20)   | <0.001                  |

a2293 observations available.  
b2609 observations available.  
cOf those with an average baseline daily energy intake of 500 to 3500 kilocalories.  
d2366 observations available.  

Abbreviations: APOE, apolipoprotein E; CDR, Clinical Dementia Rating; SD, standard deviation.

Briefly, if one considers results of \( P \geq 0.05 \) to \(< 0.10 \), there was a suggested lower AD risk with higher dietary intake of all long chain unsaturated and omega-3 FAs; and higher risk with increasing dietary intake of monounsaturated fatty acids and total fat.

4 | DISCUSSION

In this prospective, multiethnic population study, and in line with others published, we observed that two well-known LCPUFAs, EPA and DHA, were protective against the development of AD and ADRD, after adjusting for multiple covariates. Previously in this population, a dietary pattern rich in omega-3 and omega-6 PUFA, vitamin E, and folate, and lower in saturated fatty acids (SFA) and vitamin B12, was found to be protective for AD. This was coincident with high intakes of salad dressing, nuts, fish, tomatoes, poultry, cruciferous vegetables, fruits, and dark and green leafy vegetables and low intake of high-fat dairy, red meat, organ meat, and butter. A “Mediterranean-type” diet, also high in LCPUFAs, has been related to lower risk of AD in WHICAP.7,8,22-25 Our data confirm that higher intakes of LCPUFAs may be more important early in the course of disease.26

Observations from WHICAP are confirmatory of other epidemiologic reports suggesting the specific importance of EPA and DHA, compared to total PUFA intake or intake of other long-chain fatty acids. EPA and DHA are conditionally essential fatty acids, and inefficiently synthesized by the human body. Thus, optimal intake of these food components must be achieved via the diet, and their importance is underscored in relation to modifiable risk reduction for ADRD.

Perhaps it is not surprising that multiple epidemiologic studies indicate the importance of LCPUFAs for the human body and especially for the brain. An average healthy EPA- and DHA-containing human diet results in high brain levels of DHA; and DHA is the most abundant omega-3 LCPUFA in the brain contributing up to 6% of the brain’s dry weight.27 Omega-3 LCPUFA, primarily EPA and DHA, are important for cell membrane synthesis, and particularly for the nervous system.28 DHA and EPA are important for neuronal cell integrity, synaptic health, synaptic plasticity,29 and myelin synthesis.30 They are primary ingredients for neural cell structure and function.29

In the brain, as an integral cell membrane component, DHA is responsible for optimal membrane–protein interaction in signal transduction,31 enhances expression of genes such as synuclein,32 and plays an important role in neurodegeneration. Presence of DHA in the cell membrane represents aspects of a physiological lipid regulatory cascade. Splicing of the transmembrane amyloid precursor protein (APP) in neuronal cells is influenced by cell membrane lipid composition. This ultimately influences the creation of the well-characterized amyloid beta (Aβ40 and -42 oligomers that comprise brain amyloid deposits and are differentially present and diagnostic in the cerebrospinal fluid of those with mild cognitive impairment and AD.33 Data from WHICAP have shown that higher dietary intake of omega-3 PUFA is associated with lower plasma levels of Aβ42, a profile linked with lower risk of incident AD and slower cognitive decline.34 In addition, the APP-derived Aβ that contributes to formation of amyloid deposits is a natural regulator of lipid homeostasis,30 represses cholesterol production, and stimulates the production of other lipids.35 DHA also affects cholesterol metabolism.36 Dietary cholesterol increases and
| Classification | Tertiles of fatty acid intake | T1 | T2 | T3 | P for trend |
|----------------|-----------------------------|----|----|----|-------------|
| **Classification 1** | | | | | |
| **Short-chain fatty acids** | | | | | |
| Median (g/d) | 0.16 | 0.41 | 0.75 |  | |
| Incident AD | 111 | 117 | 150 |  | |
| RR (95% CI) | 1.0 (REF) | 1.14 (0.88, 1.47) | 1.52 (1.19, 1.95) | 0.0007 | |
| Age-adj HR | 1.0 (REF) | 1.05 (0.81, 1.37) | 1.24 (0.97, 1.59) | 0.0835 | |
| Multi-adj HR | 1.0 (REF) | 1.08 (0.83, 1.42) | 1.14 (0.86, 1.52) | 0.3737 | |
| **Medium-chain fatty acids** | | | | | |
| Median (g/d) | 0.90 | 1.83 | 3.17 |  | |
| Incident AD | 117 | 117 | 144 |  | |
| RR (95% CI) | 1.0 (REF) | 1.03 (0.80, 1.33) | 1.44 (1.13, 1.84) | 0.0035 | |
| Age-adj HR | 1.0 (REF) | 0.90 (0.70, 1.17) | 1.16 (0.90, 1.48) | 0.2185 | |
| Multi-adj HR | 1.0 (REF) | 0.88 (0.67, 1.16) | 1.09 (0.80, 1.49) | 0.5900 | |
| **Long-chain fatty acids** | | | | | |
| Median (g/d) | 12.86 | 20.39 | 31.02 |  | |
| Incident AD | 125 | 118 | 135 |  | |
| RR (95% CI) | 1.0 (REF) | 0.96 (0.75, 1.24) | 1.26 (0.99, 1.61) | 0.0659 | |
| Age-adj HR | 1.0 (REF) | 0.94 (0.73, 1.21) | 1.14 (0.89, 1.46) | 0.2963 | |
| Multi-adj HR | 1.0 (REF) | 0.92 (0.69, 1.22) | 1.20 (0.83, 1.74) | 0.3450 | |
| **Classification 2** | | | | | |
| **Short-chain fatty acids** | | | | | |
| Median (g/d) | 0.100 | 0.270 | 0.490 |  | |
| Incident AD | 110 | 118 | 150 |  | |
| RR (95% CI) | 1.0 (REF) | 1.09 (0.84, 1.41) | 1.48 (1.15, 1.89) | 0.0017 | |
| Age-adj HR | 1.0 (REF) | 0.99 (0.76, 1.28) | 1.18 (0.92, 1.51) | 0.1788 | |
| Multi-adj HR | 1.0 (REF) | 1.02 (0.78, 1.34) | 1.09 (0.81, 1.45) | 0.5685 | |
| **Medium-chain fatty acids** | | | | | |
| Median (g/d) | 0.340 | 0.740 | 1.320 |  | |
| Incident AD | 117 | 113 | 148 |  | |
| RR (95% CI) | 1.0 (REF) | 1.02 (0.79, 1.32) | 1.40 (1.10, 1.78) | 0.0065 | |
| Age-adj HR | 1.0 (REF) | 0.89 (0.68, 1.15) | 1.14 (0.89, 1.46) | 0.2623 | |
| Multi-adj HR | 1.0 (REF) | 0.91 (0.69, 1.20) | 1.05 (0.78, 1.41) | 0.7250 | |
| **Long-chain fatty acids** | | | | | |
| Median (g/d) | 13.66 | 21.62 | 32.74 |  | |
| Incident AD | 128 | 113 | 137 |  | |
| RR (95% CI) | 1.0 (REF) | 0.89 (0.69, 1.15) | 1.26 (0.99, 1.61) | 0.0616 | |
| Age-adj HR | 1.0 (REF) | 0.88 (0.69, 1.14) | 1.14 (0.89, 1.45) | 0.3097 | |
| Multi-adj HR | 1.0 (REF) | 0.90 (0.67, 1.20) | 1.23 (0.85, 1.79) | 0.2751 | |
| **Classification 3** | | | | | |
| **Long-chain fatty acids – 12 carbons, saturated** | | | | | |
| Median (g/d) | 7.98 | 13.55 | 21.65 |  | |
| Incident AD | 121 | 109 | 148 |  | |
| RR (95% CI) | 1.0 (REF) | 0.86 (0.66, 1.12) | 1.44 (1.13, 1.83) | 0.0029 | |

(Continues)
| Tertiles of fatty acid intake³ | T1 | T2 | T3 | P for trend |
|-------------------------------|----|----|----|-------------|
| Age-adj HR                   | 1.0 (REF) | 0.79 (0.61, 1.02) | 1.21 (0.95, 1.54) | 0.1082 |
| Multi-adj HR⁴                | 1.0 (REF) | 0.84 (0.63, 1.11) | 1.30 (0.91, 1.85) | 0.1670 |

**Long-chain fatty acids—14 carbons, saturated**

| Median (g/d) | 7.79 | 13.28 | 21.23 |
|--------------|------|-------|-------|
| Incident AD  | 121  | 110   | 147   |
| RR (95% CI)  | 1.0 (REF) | 0.86 (0.67, 1.12) | 1.43 (1.12, 1.82) | 0.0038 |
| Age-adj HR   | 1.0 (REF) | 0.78 (0.60, 1.01) | 1.19 (0.93, 1.52) | 0.1431 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.77 (0.58, 1.03) | 1.18 (0.83, 1.68) | 0.4141 |

**Long-chain fatty acids—16 carbons, saturated**

| Median (g/d) | 7.07 | 12.03 | 19.07 |
|--------------|------|-------|-------|
| Incident AD  | 123  | 108   | 147   |
| RR (95% CI)  | 1.0 (REF) | 0.86 (0.66, 1.11) | 1.39 (1.10, 1.77) | 0.0065 |
| Age-adj HR   | 1.0 (REF) | 0.76 (0.59, 0.99) | 1.17 (0.91, 1.49) | 0.1831 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.82 (0.62, 1.09) | 1.23 (0.87, 1.76) | 0.2845 |

**Long-chain fatty acids—16 carbons, unsaturated**

| Median (g/d) | 5.11 | 8.05 | 11.84 |
|--------------|------|-----|-------|
| Incident AD  | 131  | 124 | 123   |
| RR (95% CI)  | 1.0 (REF) | 0.99 (0.77, 1.26) | 1.01 (0.79, 1.29) | 0.9522 |
| Age-adj HR   | 1.0 (REF) | 0.95 (0.74, 1.22) | 0.94 (0.73, 1.20) | 0.5950 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.84 (0.64, 1.10) | 0.75 (0.53, 1.05) | 0.0943 |

**Individual long-chain fatty acids**

**DHA (C₂₂H₃₂O₂)**

| Median (g/d) | 0.06 | 0.11 | 0.24 |
|--------------|------|------|-----|
| Incident AD  | 145  | 118  | 115 |
| RR (95% CI)  | 1.0 (REF) | 0.79 (0.62, 1.01) | 0.76 (0.59, 0.97) | 0.0245 |
| Age-adj HR   | 1.0 (REF) | 0.78 (0.61, 1.00) | 0.74 (0.58, 0.94) | 0.0132 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.82 (0.63, 1.05) | 0.73 (0.57, 0.95) | 0.0184 |

**EPA (C₂₀H₃₂O₂)**

| Median (g/d) | 0.020 | 0.030 | 0.090 |
|--------------|------|------|-----|
| Incident AD  | 134  | 124  | 120 |
| RR (95% CI)  | 1.0 (REF) | 0.74 (0.58, 0.95) | 0.69 (0.54, 0.88) | 0.0030 |
| Age-adj HR   | 1.0 (REF) | 0.75 (0.59, 0.96) | 0.67 (0.52, 0.86) | 0.0015 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.84 (0.65, 1.09) | 0.74 (0.57, 0.95) | 0.0208 |

**Palmitate**

| Median (g/d) | 4.95 | 8.22 | 12.84 |
|--------------|------|------|-----|
| Incident AD  | 123  | 107  | 148 |
| RR (95% CI)  | 1.0 (REF) | 0.84 (0.65, 1.09) | 1.43 (1.12, 1.82) | 0.0034 |
| Age-adj HR   | 1.0 (REF) | 0.77 (0.60, 1.00) | 1.22 (0.96, 1.56) | 0.0925 |
| Multi-adj HR⁴ | 1.0 (REF) | 0.78 (0.58, 1.04) | 1.24 (0.87, 1.76) | 0.2659 |

**Stearate**

| Median (g/d) | 2.11 | 3.75 | 6.23 |
|--------------|------|-----|-----|
| Incident AD  | 126  | 107  | 145 |
| RR (95% CI)  | 1.0 (REF) | 0.82 (0.63, 1.06) | 1.33 (1.04, 1.69) | 0.0204 |

(Continues)
| Tertiles of fatty acid intake | T1 | T2 | T3 | P for trend |
|------------------------------|----|----|----|-------------|
| **Age-adj HR**               | 1.0 (REF) | 0.72 (0.56, 0.93) | 1.12 (0.88, 1.42) | 0.3321 |
| **Multi-adj HR**             | 1.0 (REF) | 0.75 (0.57, 1.00) | 1.23 (0.87, 1.73) | 0.2944 |
| **Oleate**                   | 
| Median (g/d)                 | 7.86 | 13.33 | 21.51 |
| Incident AD                  | 127  | 112  | 139 |
| RR (95% CI)                  | 1.0 (REF) | 0.90 (0.70, 1.16) | 1.26 (0.99, 1.61) | 0.0602 |
| Age-adj HR                   | 1.0 (REF) | 0.83 (0.64, 1.07) | 1.14 (0.89, 1.46) | 0.2802 |
| Multi-adj HR                 | 1.0 (REF) | 0.91 (0.68, 1.21) | 1.37 (0.95, 1.96) | 0.1049 |
| **Saturated fat**            | 
| Median (g/d)                 | 8.73 | 14.80 | 23.46 |
| Incident AD                  | 124  | 106  | 148 |
| RR (95% CI)                  | 1.0 (REF) | 0.84 (0.64, 1.08) | 1.37 (1.08, 1.75) | 0.0086 |
| Age-adj HR                   | 1.0 (REF) | 0.78 (0.60, 1.02) | 1.19 (0.93, 1.52) | 0.1392 |
| Multi-adj HR                 | 1.0 (REF) | 0.82 (0.62, 1.09) | 1.25 (0.88, 1.77) | 0.2606 |
| **Monounsaturated fats**     | 
| Median (g/d)                 | 8.77 | 14.73 | 23.50 |
| Incident AD                  | 124  | 117  | 137 |
| RR (95% CI)                  | 1.0 (REF) | 0.938 (0.728, 1.208) | 1.284 (1.005, 1.640) | 0.0458 |
| Age-adj HR                   | 1.0 (REF) | 0.866 (0.672, 1.116) | 1.159 (0.906, 1.483) | 0.2338 |
| Multi-adj HR                 | 1.0 (REF) | 0.968 (0.728, 1.288) | 1.421 (0.986, 2.048) | 0.0685 |
| **Polyunsaturated fats**     | 
| Median (g/d)                 | 4.52 | 7.13 | 10.66 |
| Incident AD                  | 135  | 118  | 125 |
| RR (95% CI)                  | 1.0 (REF) | 0.912 (0.712, 1.167) | 0.981 (0.768, 1.252) | 0.8631 |
| Age-adj HR                   | 1.0 (REF) | 0.869 (0.679, 1.113) | 0.931 (0.729, 1.190) | 0.5613 |
| Multi-adj HR                 | 1.0 (REF) | 0.774 (0.588, 1.020) | 0.764 (0.547, 1.067) | 0.1142 |
| **Cholesterol**              | 
| Median (g/d)                 | 125.96 | 205.40 | 316.22 |
| Incident AD                  | 110  | 128  | 140 |
| RR (95% CI)                  | 1.0 (REF) | 1.238 (0.959, 1.599) | 1.594 (1.240, 2.049) | 0.0003 |
| Age-adj HR                   | 1.0 (REF) | 1.121 (0.868, 1.449) | 1.390 (1.080, 1.789) | 0.0099 |
| Multi-adj HR                 | 1.0 (REF) | 1.146 (0.873, 1.505) | 1.380 (1.009, 1.886) | 0.0433 |
| **Omega-3**                  | 
| Median (g/d)                 | 0.63 | 0.96 | 1.40 |
| Incident AD                  | 132  | 126  | 120 |
| RR (95% CI)                  | 1.0 (REF) | 0.957 (0.750, 1.222) | 0.974 (0.760, 1.248) | 0.8309 |
| Age-adj HR                   | 1.0 (REF) | 0.949 (0.743, 1.212) | 0.942 (0.735, 1.208) | 0.6365 |
| Multi-adj HR                 | 1.0 (REF) | 0.830 (0.630, 1.093) | 0.715 (0.506, 1.010) | 0.0566 |
| **Omega-6**                  | 
| Median (g/d)                 | 3.60 | 5.87 | 8.94 |
| Incident AD                  | 134  | 120  | 124 |
| RR (95% CI)                  | 1.0 (REF) | 0.914 (0.714, 1.170) | 0.961 (0.752, 1.227) | 0.7398 |
| Age-adj HR                   | 1.0 (REF) | 0.880 (0.688, 1.126) | 0.915 (0.715, 1.169) | 0.4708 |
| Multi-adj HR                 | 1.0 (REF) | 0.765 (0.582, 1.005) | 0.765 (0.550, 1.063) | 0.1099 |
TABLE 3 (Continued)

| Tertiles of fatty acid intakea | T1  | T2    | T3   | P for trend |
|-------------------------------|-----|-------|------|------------|
| Total fat                     |     |       |      |            |
| Median (g/d)                  | 25.90 | 41.28 | 62.76 |            |
| Incident AD                   | 125  | 119   | 134  |            |
| RR (95% CI)                   | 1.0 (REF) | 0.970 (0.754, 1.248) | 1.269 (0.993, 1.623) | 0.0586 |
| Age-adj HR                    | 1.0 (REF) | 0.941 (0.731, 1.210) | 1.155 (0.902, 1.479) | 0.2528 |
| Multi-adj HRa                 | 1.0 (REF) | 1.010 (0.756, 1.348) | 1.401 (0.961, 2.041) | 0.0863 |
| DHA + EPA                     |     |       |      |            |
| Median (g/d)                  | 0.08 | 0.14  | 0.32 |            |
| Incident AD                   | 150  | 116   | 112  |            |
| RR (95% CI)                   | 1.0 (REF) | 0.798 (0.626, 1.017) | 0.752 (0.588, 0.961) | 0.0207 |
| Age-adj HR                    | 1.0 (REF) | 0.793 (0.622, 1.010) | 0.725 (0.567, 0.927) | 0.0094 |
| Multi-adj HRa                 | 1.0 (REF) | 0.827 (0.642, 1.066) | 0.731 (0.565, 0.946) | 0.0163 |

aAll models include participants with an average baseline daily energy intake of 500 to 3500 kilocalories.
bAge-adjusted (age-adj) models adjusted for chronological age only.
cMultivariate models adjusted (Multi-adj) for: age, education, race, sex, APOE4, current smoking, energy intake and the Charlson co-morbidities index.

Abbreviations: AD, Alzheimer’s disease; APOE, apolipoprotein E; CI, confidence interval; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HR, hazard ratio; RR, relative risk.

FIGURE 1  Tertile of dietary eicosapentaenoic acid (EPA) intake by Alzheimer’s disease and related dementia-free survival in Washington Heights-Inwood Columbia Aging Project.a

aMultivariate models includes participants with an average baseline daily energy intake of 500 to 3500 kilocalories and adjusted for: age, education, race, sex, apolipoprotein ε4, current smoking, energy intake, and the Charlson co-morbidities index.

DHA reduces amyloid deposition,37 the latter paralleling beneficial cognitive effects. Lower levels of DHA in the brain make dendrites more vulnerable to Aβ,38 and impairs learning in Aβ-infused rats.39 Experimental studies also show that long-term dietary DHA deficiency leads to cognitive impairment40,41 and that brain levels of DHA and partially cognitive performance can be restored by DHA administration. DHA is also the main antioxidant in the human brain.28 Thus, there are several putative pathways through which dietary LCPUFA intake may be related to AD.

DHA and EPA are fatty acids that can be acquired by the human body in two different ways. Both can be obtained via dietary intake and both can be synthesized in vivo from alpha-linolenic acid. The human
body cannot make alpha-linolenic acid; therefore it is essential, ie, the diet must provide it. Dietary intake of DHA and EPA is by orders of magnitude more bioavailable than in vivo synthesis from alpha-linolenic acid.\textsuperscript{16} Due to the important role of DHA in brain health, the brain uses protective mechanisms if dietary intake is low. DHA turnover is very slow, thus, in the short term, a limited supply may not be problematic. However, if supply remains low or absent, other fatty acids are used instead. This has several implications, including altered membrane properties and increased propensity to inflammation. However, once DHA supply increases, these substitute fatty acids are replaced by DHA.\textsuperscript{16}

As our analysis shows, it is worthwhile to note the importance of EPA and DHA compared to other dietary fatty acids and cholesterol. Cardiovascular risk factors, including both high blood and dietary cholesterol levels, in middle age, have been related to a higher risk of ADRD.\textsuperscript{1} While blood cholesterol levels are not reflective of dietary cholesterol intake, it is nonetheless of interest to evaluate both in relation to AD risk. Here we note the association of higher dietary cholesterol intake in later life, with higher AD risk, despite adjustment for cardiovascular morbidities.

While these observations from WHICAP data show protection against AD and ADRD via dietary intake of EPA and DHA, there are also published reports of no association. For example, in association with AD and ADRD, there were no associations with dietary LCPUFAs (omega-3 or omega-6) intakes over an average 9.6 years follow-up in the Rotterdam Study.\textsuperscript{42} Similarly in the Veterans Affairs Normative Aging Study, there was no association observed between dietary intake of fatty fish or omega-3 LCPUFAs and cognitive change over 6 years follow-up in elderly men.\textsuperscript{43} Erythrocyte omega-3 (DHA and EPA) levels were also not longitudinally associated with ADRD in the Canadian Study of Health and Aging over ≈10 years follow-up.\textsuperscript{44} Finally, in a randomized controlled trial of 1.5 g/d of EPA + DHA, there was no effect on cognitive function in mild to moderately depressed adults at 12 weeks.\textsuperscript{45}

We observed no associations between short- or medium-chain dietary fatty acids and ADRD. Short-chain fatty acids are of interest in ADRD and other neurological diseases because of evolving research on the gut–brain axis and the gut microbiome.\textsuperscript{46} Certain gut bacteria produce short-chain fatty acids, which are anti-inflammatory and beneficial for the gut.\textsuperscript{47} Because they are readily absorbed across the intestinal wall, they may have further systemic and central effects, and to consume more of them via the diet may be beneficial; however, there is little evidence for this. Traditionally medium-chain fatty acids have been provided to patients with malnutrition or malabsorption syndromes\textsuperscript{48} because these fatty acids require no energy for absorption, use, or storage. Some data suggest medium-chain fatty acids to be beneficial for weight control and/or reducing body fat mass, both independently and because they are readily converted to ketones. As a result, they are a main component of ketogenic diets.\textsuperscript{49} Medium-chain fatty acids have also been reported as potentially beneficial for ADRD and frailty, not only due to faster absorption and nutritional benefit, but also because conversion to ketones provides an alternative fuel source for the brain.\textsuperscript{48}

As with any observational study of older adults, there were weaknesses of our analyses. First, the geographical representativeness of the participant sample is limited to the Washington Heights-Hamilton Heights-Inwood neighborhoods of New York City. Second, as per any community-based sample, there are losses to follow-up. Details related

**FIGURE 2** Tertile of dietary docosahexaenoic acid (DHA) intake by Alzheimer’s disease and related dementia-free survival in Washington Heights-Inwood Columbia Aging Project.\textsuperscript{3}

\textsuperscript{a}Multivariate models includes participants with an average baseline daily energy intake of 500 to 3500 kilocalories and adjusted for: age, education, race, sex, apolipoprotein ε4, current smoking, energy intake, and the Charlson co-morbidities index.
to reasons for these losses in the WHICAP are published, and included refusals, unable to locate, moved, unable to schedule, and death. Third, while we used a well-accepted dietary assessment method, there are limitations to an FFQ. Notably the food list may not contain all foods consumed by participants on a regular basis. However, there was opportunity for participants to report foods consumed at least weekly that were not included on the list. Fourth, we did not measure fatty acids in blood or other biological tissue, cell, or fluid that may be more closely related to physiological function. Fifth, only one administration of the FFQ, at baseline, was conducted, therefore change in diet over the follow-up period cannot be assessed. Sixth, results are not adjusted for multiple comparisons, given this deeper exploration of novel fatty acid classes to better understand their roles. Results for DHA and EPA are robust and supported by published literature. We acknowledge their collinearity. Finally, while attempting to identify dietary intake of individual or classes of fatty acids that may be associated with ADRD, we acknowledge that nutrients and non-nutrients are not consumed in isolation and interactions among them may have played a role. Dietary recommendations should occur within the context of whole food intake and usual diet.

Our analyses of dietary fatty acid and cholesterol intake in association with ADRD in WHICAP has a number of strengths. First, this is a very-well studied, community-based cohort of underrepresented adults living in the Upper West Side of Manhattan; and these adults had dietary total fat and cholesterol intakes comparable to those observed in other aging cohort studies. Second, we used a well-accepted, validated dietary assessment method to estimate dietary fat intake. Third, we took a novel approach to better understand dietary fatty acid intake by classifying dietary fatty acids in several ways based on chain length and degree of saturation. These classifications were based on biochemical and functional activity. Fourth, we evaluated the dose of these fatty acids contributing to daily intake. Given published data on the nutraceutical role of certain fatty acids in brain health and ADRD, this was deemed the most appropriate approach. We also adjusted all analyses for energy intake, and because dietary fat contains the most energy per gram (9 kcal/g vs 4 kcal/g for both carbohydrates and protein), these two variables are highly correlated. Finally, the diagnosis of AD and ADRD was possible via an extensive neuropsychological battery, a clinical neurological examination, with subsequent adjudication by a well-trained and expert panel of neurologists and neuropsychologists.

As of 2020, there are no dietary recommendations for DHA and EPA in the United States. While it is surmised that there is insufficient scientific evidence for making an omega-3 recommendation in the United States, data such as those presented here further support the importance of these lipids as distinct and necessary dietary components in relationship to health of the aging brain.

ACKNOWLEDGMENTS

Data collection and sharing for this project was supported by the Washington Heights-Inwood Columbia Aging Project (WHICAP, PO1AG07232, R01AG037212, RF1AG054023) funded by the National Institute on Aging (NIA) and by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873. This research project was also supported through the State University of New York, and the LipidDiEt Consortium (grant agreement No 211696). This manuscript has been reviewed by WHICAP investigators for scientific content and consistency of data interpretation with previous WHICAP Study publications. We acknowledge the WHICAP study participants and the WHICAP research and support staff for their contributions to this study.

REFERENCES

1. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF, Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ. 2002;325:932-933.
2. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr. 2007;85:1142-1147.
3. Morris MC. The role of nutrition in Alzheimer’s disease: epidemiological evidence. Eur J Neuro. 2009;16(suppl 1):1-7.
4. Eskelinen MH, Ngandu T, Tuomilehto J, Soininen H, Kivipelto M. Midlife healthy-diet index and late-life dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord. 2011;1:103-112.
5. Chiu CC, Su KP, Cheng TC, et al. The effects of omega-3 fatty acids monotherapy in Alzheimer’s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:1538-1544.
6. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: omegAD study: a randomized double-blind trial. Arch Neurol. 2006;63:1402-1408.
7. Scarmeas N, Luchsinger JA, Mayeux R, Stern Y. Mediterranean diet and Alzheimer disease mortality. Neurology. 2007;69:1084-1093.
8. Scarmeas N, Stern Y, Tang MX, Mayeux R, Luchsinger JA. Mediterranean diet and risk for Alzheimer’s disease. Ann Neurol. 2006;59:912-921.
9. Scarmeas N, Anastasiou CA, Yannakoulia M. Nutrition and prevention of cognitive impairment. Lancet Neurol. 2018;17:1006-1015.
10. Whitney E, Rolfes SR. Understanding Nutrition. 10th ed. Belmont, CA: Thomson Wadsworth; 2005.
11. Brondz I. Fatty Acids. Reference Module in Chemistry, Molecular Sciences and Chemical Engineering. Amsterdam: Elsevier; 2016.
12. Biochemistry of Lipids: Lipoproteins and Membranes. Amsterdam: Elsevier Science; 2015.
13. Hishikawa D, Valentine WJ, Iizuka-Hishikawa Y, Shindou H, Shimizu T. Metabolism and functions of docosahexaenoic acid-containing membrane glycerophospholipids. FEBS Lett. 2017;591:2730-2744.
14. Rodwell VW, Bender DA, Botham KM, Kennelly PJ, Weil PA. Harpers Illustrated Biochemistry. 31st ed. New York, New York: McGraw-Hill Education; 2018.
15. U.S. Department of Agriculture, Agricultural Research Service. FoodData Central. 2019. fdc.nal.usda.gov.
16. Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr. 2014;2:443-463.
17. Panel on Micronutrients, Panel on the Definitions of Dietary Fiber, Subcommittee on Upper Reference Levels of Nutrients, Subcommittee on Interpretation and Uses of Dietary Reference Intake, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. In: Institute of Medicine Food and Nutrition Board, ed. Dietary Reference Intakes. Washington, D.C., National Academies Press, 2005.
18. Stern Y, Andrews H, Pittman J, et al. Diagnosis of dementia in a heterogeneous population. Development of a neuropsychological paradigm-based diagnosis of dementia and quantified correction for the effects of education. Arch Neurol. 1992;49:453-460.

19. Colditz GA, Willett WC, Stampfer MJ, et al. The influence of age, relative weight, smoking, and alcohol intake on the reproducibility of a dietary questionnaire. Int J Epidemiol. 1987;16:392-398.

20. Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol. 2002;59:1258-1263.

21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.

22. Gu Y, Brickman AM, Stern Y, et al. Mediterranean diet and brain structure in a multiethnic elderly cohort. Neurology. 2015;85:1744-1751.

23. Gu Y, Luchsinger JA, Stern Y, Scarmeas N. Mediterranean diet, inflammation and metabolic biomarkers, and risk of Alzheimer’s disease. J Alzheimers Dis. 2010;22:483-492.

24. Gu Y, Nieves JW, Luchsinger JA, Scarmeas N. Food combination and Alzheimer disease risk: a protective diet. Arch Neurol. 2010;67:699-706.

25. Scarmeas N, Stern Y, Mayeux R, Manly JJ, Schupf N, Luchsinger JA. Mediterranean diet and mild cognitive impairment. Arch Neurol. 2009;66:216-225.

26. Canhada S, Castro K, Perry IS, Luft VC. Omega-3 fatty acids’ supplementation in Alzheimer’s disease: a systematic review. Nutr Neurosci. 2018;21:529-538.

27. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res. 1999;56:565-570.

28. Hashimoto M, Hossain S, Al Mamun A, Matsuzaki K, Arai H. Docosahexaenoic acid: one molecule diverse functions. Crit Rev Biotechnol. 2017;37:579-597.

29. Kamphuis PJ, Wurtman RJ. Nutrition and Alzheimer’s disease: preclinical concepts. Eur J Neurol. 2009;16(suppl 1):12-18.

30. Grimm MW, Michaelson DM, Hartmann T. Omega-3 fatty acids, lipids, and apoE lipiddation in Alzheimer’s disease: a rationale for multi-nutrient dementia prevention. J Lipid Res. 2017;58:2083-2101.

31. Litman BJ, Mitchell DC. A role for phospholipid polysaturination in modulating membrane protein function. Lipids. 1996;31(suppl):S193-S197.

32. Kitajka K, Puskas LG, Zvara A, et al. The role of n-3 polysaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci U S A. 2002;99:2619-2624.

33. Amtul Z, Uhrig M, Supino R, Beyreuther K. Phospholipids and a logical effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28:667-683.

34. Gu Y, Schupf N, Cosentino SA, Luchsinger JA, Scarmeas N. Nutrient intake and plasma beta-amyloid. Neurology. 2012;78:1832-1840.

35. Martins IU, Hone E, Foster JK, et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer’s disease and cardiovascular disease. Mol Psychiatry. 2006;11:721-736.

36. Kariv-Inbal Z, Yacobson S, Berkecz R, et al. The isoform-specific pathological effects of apoE4 in vivo are prevented by a fish oil (DHA) diet and are modified by cholesterol. J Alzheimers Dis. 2012;28:677-687.

37. Broersen LM, Kuipers AA, Balvers M, et al. A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AbetaPPswe/PS1dE9 mice. J Alzheimers Dis. 2013;33:177-190.

38. Calon F, Lim GP, Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer’s disease mouse model. Neuron. 2004;43:633-645.

39. Hashimoto M, Hossain S, Agdul H, Shido O. Docosahexaenoic acid-induced amelioration on impairment of memory learning in amyloid beta-infused rats relates to the decreases of amyloid beta and cholesterol levels in detergent-insoluble membrane fractions. Biochim Biophys Acta. 2005;1738:91-98.

40. Salem NJr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids. 2001;36:945-959.

41. Salem NJr, Moriguchi T, Greiner RS, et al. Alterations in brain function after loss of docosahexaenoate due to dietary restriction of n-3 fatty acids. J Mol Neurosci. 2001;16:299-307. discussion 17-21.

42. Devore EE, Grodstein F, van Rooij FJ, et al. Dietary intake of fish and omega-3 fatty acids in relation to long-term dementia risk. Am J Clin Nutr. 2009;90:170-176.

43. van de Rest O, Spiro A, 3rd, Krall-Kaye E, Gelieijnse JM, de Groot LC, Tucker KL. Intakes of (n-3) fatty acids and fatty fish are not associated with cognitive performance and 6-year cognitive change in men participating in the Veterans Affairs Normative Aging Study. J Nutr. 2009;139:2329-2336.

44. Kroger E, Verreault R, Carmichael PH, et al. Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging. Am J Clin Nutr. 2009;90:184-192.

45. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polysaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr. 2008;99:421-431.

46. Castillo-Alvarez F, Marzo-Sola ME. Role of the gut microbiota in the development of various neurological diseases. Neurologia. 2019. pii: S0213-4853(19)30082-9. https://doi.org/10.1016/j.nrl.2019.03.017. https://pubmed.ncbi.nlm.nih.gov/31340904/.

47. Ho L, Ono K, Tsuji M, Mazzola P, Singh R, Pasinetti GM. Protective roles of intestinal microbiota derived short chain fatty acids in Alzheimer’s disease-type beta-amyloid neuropathological mechanisms. Expert Rev Neurother. 2018;18:83-90.

48. Hernandez Morante JJ, Gomez Martinez C, Morillas-Ruiz JM. Dietary factors associated with frailty in old adults: a review of nutritional interventions to prevent frailty development. Nutrients. 2019;11:102.

49. Augustin K, Khabush A, Williams S, et al. Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders. Lancet Neurol. 2018;17:84-93.

50. Noble JM, Schupf N, Manly JJ, Andrews H, Tang MX, Mayeux R. Secular trends in the incidence of dementia in a multi-ethnic community. J Alzheimers Dis. 2017:60:1065-1075.

How to cite this article: Gustafson DR, Bäckman K, Scarmeas N, et al. Dietary fatty acids and risk of Alzheimer’s disease and related dementias: Observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP). Alzheimer’s Dement. 2020;16:1638–1649. https://doi.org/10.1002/alz.12154